Patents by Inventor David Paul Humphreys

David Paul Humphreys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12091450
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: September 17, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Paul Humphreys, Ralph Adams, James Heads, Shirley Jane Peters
  • Publication number: 20230374148
    Abstract: The present invention provides binding molecule or molecules that are able to multimerise CD45 to induce cell death of a cell expressing CD45 without also inducing significant cytokine release. For example, the invention provides antibodies against CD45, wherein the antibodies comprise at least two different paratopes each specific for a different epitope of CD45. The antibodies may be used to cross-link CD45 on the surface of cells. The antibodies may be used in a variety of therapeutic ways including to deplete cells, for example prior to cell transplantation.
    Type: Application
    Filed: October 14, 2021
    Publication date: November 23, 2023
    Inventors: Stephen Edward RAPECKI, Ralph ADAMS, David Paul HUMPHREYS, Helen Margaret FINNEY, Rosemary Frances BITHELL
  • Publication number: 20230087378
    Abstract: The present invention relates to a multi-specific antibody having specificity for human IL-13, human IL-17A and/or human IL-17F. The invention further relates to methods for producing the multi-specific antibody and to its therapeutic use for the treatment of atopic dermatitis and other diseases.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 23, 2023
    Inventors: Adnan Rahman Khan, Sam Philip Heywood, David Paul Humphreys, Daniel John Lightwood, Emma Dave, Emily Mary Cairistine Barry, Sarah Jayne Stanyon
  • Patent number: 11427650
    Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: August 30, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
  • Publication number: 20220267476
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 25, 2022
    Inventors: Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11401349
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 2, 2022
    Assignee: UCB Biopharma SRL
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11352414
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 7, 2022
    Inventors: Farnaz Fallah-Arani, Robert Anthony Griffin, David Paul Humphreys, Shirley Jane Peters, Bryan John Smith, Paul Edward Stephens
  • Patent number: 11345760
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 31, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 11261470
    Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti FcRn antibodies and proteins made by the methods described herein.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Philip Jonathan Bassett, David Paul Humphreys, Pareshkumar Manjibhai Patel
  • Publication number: 20210324111
    Abstract: The present invention provides a multispecific antibody molecule comprising at least two binding domains each with a variable heavy region VH and a variable light region VL, wherein each binding domain is specific for an antigen and comprises 6 CDRs, characterised in that at least one binding domain comprises a variable heavy region, VHA, having a framework comprising valine at position (5), lysine at position (13), alanine at position (24) and threonine at position (96) with the proviso that CDRH3 in VHA is other than RYYSAMPFAY (SEQ ID NO:29) and a variable light region, VLA, having a framework comprising leucine at position (11) and glutamine at position (103).
    Type: Application
    Filed: December 18, 2017
    Publication date: October 21, 2021
    Inventors: Pallavi Bhatta, David Paul Humphreys
  • Patent number: 11091542
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 17, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Patent number: 11059911
    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: July 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Publication number: 20200377578
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon MacKenzie, Matthew Cox
  • Patent number: 10759844
    Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: September 1, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventor: David Paul Humphreys
  • Patent number: 10752676
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: August 25, 2020
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenzie, Matthew Cox
  • Publication number: 20200157204
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Application
    Filed: December 17, 2019
    Publication date: May 21, 2020
    Inventors: David Paul Humphreys, Ralph Adams, James Heads, Shirley Jane Peters
  • Publication number: 20200055959
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III):V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, nindependently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V1 and V2, in particular where a disulphide bond is present.
    Type: Application
    Filed: September 17, 2019
    Publication date: February 20, 2020
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 10562966
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: February 18, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters, Ralph Adams, James Heads
  • Patent number: 10472426
    Abstract: The present disclosure provides a binding protein comprising: a polypeptide heavy chain comprising: VH1-(X1)n-VH2—CH (X2)y wherein VH1 is a first variable domain, VH2 is a second variable domain, CH is a constant domain, X1 represents an amino acid or peptide, X2 represents an Fc region, n is 0 or 1 and y is independently 1 or 2, and a polypeptide light chain comprising: VL1-(X1)n-VL2-C wherein VL1 is a first variable domain, VL2 is a second variable domain, C is a constant domain, X1 represents an amino acid or peptide and n is 0 or 1, wherein the heavy chain and light chain are aligned such that VH1 and VL1 form a first binding domain, and VH2 and VL2 form a second binding domain and wherein: there is a disulfide bond between VH1 and VL1, and/or there is a disulfide bond between VH2 and VL2, and use thereof in treatment.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: November 12, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, David Paul Humphreys
  • Patent number: 10457748
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III): V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 29, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys